Overview of the Flaviviridae with an emphasis on the Japanese encephalitis group viruses

Laboratory Medicine

Volumn 40, Issue 8, 2009, Pages 493-499

  Schweitzer, Beth K ^a   Chapman, Nora M ^b   Iwen, Peter C ^b  

^a Nebraska Public Health Laboratory   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

EXPOSURE; FLAVIVIRUS; HUMAN; JAPANESE ENCEPHALITIS VIRUS; MOSQUITO; MURRAY VALLEY ENCEPHALITIS VIRUS; NONHUMAN; REVIEW; ST LOUIS FLAVIVIRUS; VIROGENESIS; VIRUS CULTURE; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS REPLICATION; WEST NILE FLAVIVIRUS;

FLAVIVIRIDAE; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; MURRAY VALLEY ENCEPHALITIS VIRUS; ST. LOUIS ENCEPHALITIS VIRUS; WEST NILE VIRUS;

EID: 77951958425     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LM5YWS85NJPCWESW     Document Type: Review

References (62)

1. Alatoom A, Payne D. An overview of arboviruses and bunyaviruses. Lab Med. 2009;40:237-240.
2. Tomori O. Yellow fever: The recurring plague. Crit Rev Clin Lab Sci. 2004; 41:391-427.
3. McCaw WD. Walter Reed: A Memoir. Yellow fever: A Compilation of various publications. Results of the Work of Maj. Walter Reed, Medical Corps, United States Army, and the Yellow Fever Commission. 1911: 8-12.
4. Gubler DJ, Kuno G, Markoff L. Flaviviruses. In: Knipe D, Howley P, eds. Fields Virology. Philadelphia, PA: Lippincott Williams and Wilkins; 2007:1153-1252.
5. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: The spread and resurgence of JE, West Nile and Dengue viruses. Nat Med. 2004;10:S98-109.
6. Weaver SC, Barrett AD. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol. 2004;2:789-801.
7. Petersen LR, Marfin AA. Shifting epidemiology of Flaviviridae. J Travel Med. 2005;12:S3-11.
8. Hienz, FX, Collett MS, Purcell RH, et al. Flaviviridae. In: van Ragenmorteil CM, Fauquet CM, Bishop DHK, et al, eds. Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses. San Diego, CA: Academic Press; 2000; 7: 611-614.
9. Petersen LR, Roehrig JT. West Nile virus: A reemerging global pathogen. Emerg Infect Dis. 2001;7:611-614 (Pubitemid 32845245)
10. Lindenbach B. Flaviviridae. In: Knipe D, Howley P, eds. The Viruses and Their Replication. Philadelphia, PA: Lippincott Williams and Wilkins; 2007:1101-1154.
11. Markoff L, Falgout B, Chang A. A conserved internal hydrophobic domain mediates the stable membrane integration of the Dengue virus capsid protein. Virology. 1997;233:105-117. (Pubitemid 27348772)
12. Sanchez MD, Pierson TC, McAllister D, et al. Characterization of neutralizing antibodies to West Nile virus. Virology. 2005;336:70-82. (Pubitemid 40603672)
13. Stiasny K, Kossl C, Lepault J, et al. Characterization of a structural intermediate of flavivirus membrane fusion. PLoS Pathog. 2007;3:20. (Pubitemid 46318420)
14. Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res. 2003;59:23-61.
15. Stadler K, Allison SL, Schalich J, et al. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997;71:8475-8481. (Pubitemid 27446428)
16. Bray M, Lai CJ. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology. 1991;185:505-508.
17. Macdonald J, Tonry J, Hall RA, et al. NS1 protein secretion during the acute phase of West Nile virus infection. J Virol. 2005;79:13924-13933. (Pubitemid 41552691)
18. Chung KM, Liszewski MK, Nybakken G, et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci USA. 2006;103:19111-19116. (Pubitemid 350002836)
19. Mehlhop E, Whitby K, Oliphant T, et al. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol. 2005;79:7466-7477. (Pubitemid 40756783)
20. Day JF. Predicting St. Louis encephalitis virus epidemics: Lessons from recent, and not so recent, outbreaks. Annu Rev Entomol. 2001;46:111-138.
21. Figueiredo LT. The Brazilian flaviviruses. Microbes Infect. 2000;2:1643-1649.
22. Poidinger M, Hall RA, Mackenzie JS. Molecular characterization of the Japanese encephalitis serocomplex of the flavivirus genus. Virology. 1996;218:417-421. (Pubitemid 26163836)
23. Weissenbock H, Kolodziejek J, Url A, et al. Emergence of Usutu virus, an African mosquito-borne flavivirus of the Japanese encephalitis virus group, central Europe. Emerg Infect Dis. 2002;8:652-656. (Pubitemid 34764727)
24. Mazurek JM, Winpisinger K, Mattson BJ, et al. The epidemiology and early clinical features of West Nile virus infection. Am J Emerg Med. 2005;23:536-543. (Pubitemid 41008009)
25. Petersen LR, Marfin AA. West Nile virus: A primer for the clinician. Ann Intern Med. 2002;137:173-179. (Pubitemid 34827513)
26. Mitamura T, Kitaoka M, Mori K, et al. Isolation of Japanese epidemic encephalitis for mosquitoes caught in nature. Tokyo Iji Shinshi. 1938;62:820-831.
27. Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry. 2000;68:405-415.
28. CDC. Health Information for International Travel 2008. In: Services. UDoHaH, ed. Prevention of Specific Infectious Diseases, Japanese Encephatitis. Atlanta, GA: US Government Printing Office; 2007.
29. van den Hurk AF, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol. 2009;54:17-35.
30. Erlanger TE, Weiss S, Keiser J, et al. Past, present, and future of Japanese encephalitis. Emer Infect Dis. 2009;15:1-7.
31. CDC. Inactivated Japanese encephalitis virus vaccine, recommendations of the Advisory Committee on Immunization Practeces. Morb Mortal Week Rep. 1993;42:RR-01.
32. Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005;18:387-394. (Pubitemid 41345295)
33. Mackenzie JS, Broom AK. Australian X disease, Murray Valley encephalitis and the French connection. Vet Microbiol. 1995;46:79-90.
34. Douglas MW, Stephens DP, Burrow JN, et al. Murray Valley encephalitis in an adult traveller complicated by long-term flaccid paralysis: Case report and review of the literature. Trans R Soc Trop Med Hyg. 2007;101:284-288.
35. Spencer JD, Azoulas J, Broom AK, et al. Murray Valley encephalitis virus surveillance and control initiatives in Australia. National Arbovirus Advisory Committee of the Communicable Diseases Network Australia. Commun Dis Intell. 2001;25:33-47.
36. Stich A, Gunther S, Drosten C, et al. Clinical and laboratory findings on the first imported case of Murray Valley encephalitis in Europe. Clin Infect Dis. 2003;37:19-21.
37. Wallace MJ, Smith DW, Broom AK, et al. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol. 2003;84: 1723-1728.
38. Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007. Am J Trop Med Hyg. 2008;79:974-979.
39. Day JF, Stark LM. Frequency of Saint Louis encephalitis virus in humans from Florida, USA: 1990-1999. J Med Entomol. 2000;37:626-633.
40. Pugachev KV, Guirakhoo F, Mitchell F, et al. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg. 2004;71:639-645. (Pubitemid 39601165)
41. Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 1999;286:2333-2337. (Pubitemid 30016893)
42. Blitvich BJ. Transmission dynamics and changing epidemiology of West Nile virus. Anim Health Res Rev. 2008;9:71-86.
43. Hayes EB. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11:1174-1179. (Pubitemid 41045322)
44. Hayes EB. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11:1167-1173. (Pubitemid 41045321)
45. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: Results of a household-based seroepidemiological survey. Lancet. 2001;358:261-264.
46. Schweitzer BK, Kramer WL, Sambol AR, et al. Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic. Clin Vac Immun. 2006;13:314-318.
47. Dauphin G, Zientara S. West Nile virus: Recent trends in diagnosis and vaccine development. Vaccine. 2007;25:5563-5576. (Pubitemid 47031364)
48. Minke JM, Siger L, Karaca K, et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl. 2004:221-230.
49. Wang T, Fikrig E. Immunity to West Nile virus. Curr Opin Immunol. 2004;16:519-523.
50. Association of State and Territorial Health Officials. Public Health Confronts the Mosquito: Developing Sustainable State and Local Mosquito Control Programs. Washington DC: Association of State and Territorial Health Officials; 2005.
51. Shi PY, Wong SJ. Serologic diagnosis of West Nile virus infection. Expert Rev Mol Diagn. 2003;3:733-741. (Pubitemid 37428960)
52. Campbell GL, Grady LJ, Huang C, et al. Laboratory testing for West Nile Virus: Panel discussion. Ann N Y Acad Sci. 2001;951:179-194. (Pubitemid 34060044)
53. Petersen LR, Barrett AD. Arthropod-Borne Flaviviruses. In: Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. 3rd ed. ASM Press; 2009:1173-1214.
54. Zhang W, Wu J, Li Y, et al. Rapid and accurate in vitro assays for detection of West Nile Virus in blood and tissues. Trans Med Rev. 2009;23:146-154.
55. Kapoor H, Signs K, Somsel P, et al. Persistence of West Nile Virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. J Clin Virol. 2004;31:289-291. (Pubitemid 39371062)
56. Prince HE, Tobler LH, Lape-Nixon M, et al. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol. 2005;43:4316-4320. (Pubitemid 41298207)
57. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile Virus encephalitis cases. Emerg Infect Dis. 2003;9:376-379. (Pubitemid 36330881)
58. AuBuchon JP. Meeting transfusion safety expectations. Ann Intern Med. 2005;143:537-538.
59. Wang T, Scully E, Yin Z, et al. IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection. J Immunol. 2003;171:2524-2531. (Pubitemid 37025562)
60. Wang Y, Lobigs M, Lee E, et al. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol. 2003;77:13323-13334. (Pubitemid 37494327)
61. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65-91.
62. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile Virus infection. J Virol. 2004;78:8312-8321. (Pubitemid 38944315)